Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418451

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10091
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.</p><p> </p><p> </p><p> </p><p>We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:22:40 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418452

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10092
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:23:43 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418453

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10093
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:25:30 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418455

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	9996
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell

418456

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to promote research into muscular dystrophy conditions.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	9997
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including muscular dystrophies. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>Research on novel approaches to treating neuromuscular disease including Duchenne muscular dystrophy is being carried out by the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Trust and the University College London Institute of Child Health.</p><p> </p><p> </p><p> </p><p>The NIHR Health Technology Assessment programme is currently seeking to commission research on the effectiveness and cost-effectiveness of mechanical insufflation-exsufflation devices when compared to other methods of sputum clearance commonly used in children and young people with neuromuscular disease.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:27:44 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell

418458

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effect of eye clinic liaison officers on improving patient health and social care; and what progress he has made on increasing the provision of such officers.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	9980
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9977 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
tabling member	253 label Biography information for Mr Laurence Robertson

418459

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding his Department provides for eye clinic liaison officers.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	9977
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9980 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
tabling member	253 label Biography information for Mr Laurence Robertson

418460

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Births
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the (a) extent and (b) effectiveness of sharing of best practice of implementation of guidance on multiple pregnancies between NHS hospital trusts.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	9978
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>Evidence based advice on the care of women with multiple pregnancies is set out in the National Institute for Health and Care Excellence (NICE ) Clinical Guidelines ‘Multiple Pregnancies – The management of twin and triplet pregnancies in the antenatal period’. In line with these guidelines, we would expect clinical care for women with twin and triplet pregnancies to be provided by a nominated multidisciplinary team consisting of a core team, including named specialist obstetricians, who have experience and knowledge of managing twin and triplet pregnancies. The Department has not undertaken an assessment of the effectiveness of the implementation of the NICE guidelines.</p><p> </p><p> </p><p> </p><p>Local maternity care providers are responsible for determining how best to deliver services for women with multiple pregnancies in their area. In doing so we would expect them to give due regard to NICE guidelines.</p><p> </p><p> </p><p> </p><p>NHS England has asked Baroness Julia Cumberlege to lead a major review of maternity services to modernise care for women and babies across the country, as first set out in NHS England’s Five Year Forward View. The independent review group is assessing current maternity care provision, considering the evidence on different models of care and will make recommendations on how services should be developed to meet the changing needs of women and babies. The group met for the first time on 23 April and it plans to report by the end of the year. More information is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/2015/05/29/julia-cumberlege-2/" target="_blank">http://www.england.nhs.uk/2015/05/29/julia-cumberlege-2/</a></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 16/09/2015 15:29:19 answering member 3988 label Biography information for Ben Gummer
tabling member	253 label Biography information for Mr Laurence Robertson

418463

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10010
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10011 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

418464

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10011
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10010 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper